Circulating microRNA as diagnostic biomarkers for haematological cancers: a systematic review and meta-analysis

References

• Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368:1894–1907. doi:10.1016/S0140-6736(06)69780-817126723
   PubMed Web of Science ®Google Scholar
• Rodriguez-Abreu D, Bordoni A, Zucca E. Epidemiology of hemato- logical malignancies. Ann Oncol. 2007;18. doi:10.1093/annonc/mdl443
   PubMed Web of Science ®Google Scholar
• Stone RM, O’Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2004;98–117. doi:10.1182/asheducation-2004.1.9815561679
   PubMedGoogle Scholar
• Gregory TK, Wald D, Chen Y, Vermaat JM, Xiong Y, Tse W. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. J Hematol Oncol. 2009;2:23. doi:10.1186/1756-8722-2-2319490647
   PubMed Web of Science ®Google Scholar
• Slater DN. The new World Health Organization classification of haematopoietic and lymphoid tumours: A dermatopathological perspective. Br J Dermatol. 2002;147:633–639.12366406
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Harris NL, Stein HJ, Vardiman JW. Pathology and genetics: tumours of haematopoietic and lymphoid tissues (WHO Classification of Tumours). IARC. 2001;3:1–351.
   Google Scholar
• Kalia M. Biomarkers for personalized oncology: recent advances and future challenges. Metabolism. 2015;64:S16–S21. doi:10.1016/j.metabol.2014.10.02725468140
   PubMed Web of Science ®Google Scholar
• Orfao A, Lopez A, Flores J, Almeida J. Diagnosis of hematological malignancies: new applications for flow cytometry. Hematol (EHA). 2006;2:6–13.
   Google Scholar
• Belov L, Huang P, Barber N, Mulligan SP, Christopherson RI. Identification of repertoires of surface antigens on leukemias using an antibody microarray. Proteomics. 2003;3:2147–2154.
   Google Scholar
• Martin DJ, Anders HL. MicroRNA and cancer. Mol Oncol. 2012;6:590–610. doi:10.1016/j.molonc.2012.09.00623102669
   PubMed Web of Science ®Google Scholar
• Ruiz-Arguelles A, Rivadeneyra-Espinoza L, Duque RE, Orfao A. Report on the second Latin American consensus conference for flow cytometric immunophenotyping of hematological malignancies. Cytometry B Clin Cytom. 2006;70:39–44. doi:10.1002/cyto.b.2008316353215
   PubMedGoogle Scholar
• Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2001;1:118–129. doi:10.1038/3510107211905803
   PubMed Web of Science ®Google Scholar
• Schroers R, Baraniskin A, Heute C, et al. Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas. Eur J Haematol. 2010;85:236–242. doi:10.1111/j.1600-0609.2010.01475.x20528903
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–269. doi:10.1038/nrc184016557279
   PubMed Web of Science ®Google Scholar
• Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001;294:853–858. doi:10.1126/science.106492111679670
   PubMed Web of Science ®Google Scholar
• Sevcikova S, Kubiczkova L, Sedlarikova L, Slaby O, Hajek R. Serum miR-29a as a marker of multiple myeloma. Leuk Lymphoma. 2013;54:189–191. doi:10.3109/10428194.2013.79605222712836
   PubMed Web of Science ®Google Scholar
• Lin S, Pan L, Guo S, et al. Prognostic role of microRNA-181a/b in hematological malignancies: a meta-analysis. PLoS One. 2013;8:e59532. doi:10.1371/journal.pone.005953223533632
   PubMed Web of Science ®Google Scholar
• Baraniskin A, Kuhnhenn J, Schlegel U, et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011;117:3140–3146. doi:10.1182/blood-2010-09-30868421200023
   PubMed Web of Science ®Google Scholar
• Fang C, Zhu DX, Dong HJ, et al. Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. Ann Hematol. 2012;91:553–559. doi:10.1007/s00277-011-1350-921987025
   PubMed Web of Science ®Google Scholar
• Guo HQ, Huang GL, Guo CC, Pu XX, Lin TY. Diagnostic and prognostic value of circulating miR-221 for extranodal natural killer/T-cell lymphoma. Dis Markers. 2010;29:251–258. doi:10.1155/2010/47469221206010
   PubMed Web of Science ®Google Scholar
• Ohyashiki K, Umezu T, Yoshizawa S, et al. Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin’s lymphoma. PLoS One. 2011;6:e16408. doi:10.1371/journal.pone.001640821383985
   PubMed Web of Science ®Google Scholar
• Hao M, Zang M, Qin Y, et al. Circulating MIR-19A and MIR-92A in serum as potential biomarkers for detecting multiple myeloma. Clin Lymphoma Myeloma and Leuk. 2013;13:S198–9.
   PubMedGoogle Scholar
• Kubiczkova L, Kryukov F, Slaby O, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and mono- clonal gammopathy of undetermined significance. Haematologica. 2014;99:511–518. doi:10.3324/haematol.2013.09350024241494
   PubMed Web of Science ®Google Scholar
• Zhi F, Cao X, Xie X, et al. Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia. Plos One. 2013;8:e56718.
   Google Scholar
• Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–10518. doi:10.1073/pnas.080454910518663219
   PubMed Web of Science ®Google Scholar
• Ferracin M, Veronese A, Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn. 2010;10:297–308. doi:10.1586/erm.10.1120370587
   PubMed Web of Science ®Google Scholar
• Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010;101:2087–2092. doi:10.1111/j.1349-7006.2010.01605.x20624164
   PubMed Web of Science ®Google Scholar
• Xie HT, Chu ZX, Wang H. Serum microRNA expression profile as a biomarker in diagnosis and prognosis of acute myeloid leukemia. J Clin Pediatr. 2012;30:421–424.
   Google Scholar
• Yoshizawa S, Ohyashiki JH, Ohyashiki M, et al. Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J. 2012;2:e53. doi:10.1038/bcj.2011.5122829237
   PubMed Web of Science ®Google Scholar
• Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–536. doi:10.7326/0003-4819-155-8-201110180-0000922007046
   PubMed Web of Science ®Google Scholar
• Deville WL, Buntinx F, Bouter LM, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol. 2002;2:9. doi:10.1186/1471-2288-2-912097142
   PubMedGoogle Scholar
• Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: A software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6:31. doi:10.1186/1471-2288-6-3116836745
   PubMedGoogle Scholar
• Quan L, Liu L. Weiming Li: identification of circulating microRNAs as biomarkers in diagnosis of haematological cancers: a meta-analysis. Tumor Biol. 2014;35:10467–10478. doi:10.1007/s13277-014-2364-4
   PubMedGoogle Scholar
• Li-Hua X, Guo Y, Xue-Li Z, et al. Blood-based circulating microRNAs are potential diagnostic biomarkers for leukaemia: results from a meta-analysis. Cell Physiol Biochem. 2016;38:939–949. doi:10.1159/00044304626938054
   PubMedGoogle Scholar
• Fayyad-Kazan H, Bitar N, Najar M, et al. Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Transl Med. 2013;11:31. doi:10.1186/1479-5876-11-3123391324
   PubMed Web of Science ®Google Scholar
• Wang F, Wang XS, Yang GH, et al. miR-29a and miR-142-3p downregulation and diagnostic implication in hu- man acute myeloid leukemia. Mol Biol Rep. 2012;39:2713–2722. doi:10.1007/s11033-011-1026-521678057
   PubMed Web of Science ®Google Scholar
• Hao M, Zang M, Yu Q, et al. Serum miR-4254, miR-19a and miR-33b are potential markers for diagnosis and prognostic evaluation in multiple myeloma. Blood. 2013;122. doi:10.1182/blood-2012-12-471029
   Google Scholar
• Qu X, Zhao M, Wu S, et al. Circulating microrna 483-5p in multiple myeloma as a novel biomarker for diagnosis and predicting survival. Blood. 2013;122. doi:10.1182/blood-2012-12-471029
   Web of Science ®Google Scholar
• Hao M, Zang M, Wendlandt E, et al. Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int J Cancer. 2015;136:1835–1844. doi:10.1002/ijc.2919925220540
   PubMed Web of Science ®Google Scholar
• Yu J, Qiu X, Shen X, et al. miR-202 expression concentration and its clinical significance in the serum of multiple myeloma patients. Ann Clin Biochem. 2014;51:543–549. doi:10.1177/000456321350115524048721
   PubMed Web of Science ®Google Scholar
• Jones CI, Zabolotskaya MV, King AJ, et al. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer. 2012;107:1987–1996. doi:10.1038/bjc.2012.52523169280
   PubMed Web of Science ®Google Scholar
• Huang S, Lu Y, Liu J. Expression and clinical significance of circulating miR-335 in patients with acute myeloid leukemia. Exp Lab Med. 2015;33:147–149.
   Google Scholar
• Elhamamsy AR, El Sharkawy MS, Zanaty AF, et al. Circulating miR-92a, miR-143 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. Int J Mol Cell Med Spring. 2017;6(2):76–86.
   Google Scholar
• Swellam M, El-Khazragy N. Clinical impact of circulating microRNAs as blood-based marker in childhood acute lymphoblastic leukemia. Tumor Biol. 2016;37:10571–10576. doi:10.1007/s13277-016-4948-7
   PubMedGoogle Scholar
• Frankfurt O, Licht JD, Tallman MS. Molecular characterization of acute myeloid leukemia and its impact on treatment. Curr Opin Oncol. 2007;19:635–649. doi:10.1097/CCO.0b013e3282f10e5517906465
   PubMed Web of Science ®Google Scholar
• Haferlach T, Bacher U, Haferlach C, Kern W, Schnittger S. Insight into the molecular pathogenesis of myeloid malignancies. Curr Opin Hematol. 2007;14:90–97. doi:10.1097/MOH.0b013e328016849017255785
   PubMed Web of Science ®Google Scholar
• Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res. 2011;183:25–35.21509679
   PubMedGoogle Scholar
• Jabbour EJ, Estey E, Kantarjian HM. Adult acute myeloid leukemia. Mayo Clin Proc. 2006;81:247–260. doi:10.4065/81.2.24716471082
   PubMed Web of Science ®Google Scholar
• McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem. 2011;57:833–840. doi:10.1373/clinchem.2010.15719821487102
   PubMed Web of Science ®Google Scholar
• Tanaka M, Oikawa K, Takanashi M, et al. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One. 2009;4:e5532. doi:10.1371/journal.pone.000553219440243
   PubMed Web of Science ®Google Scholar
• Redova M, Poprach A, Nekvindova J, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 2012;10:55. doi:10.1186/1479-5876-10-23322440013
   PubMed Web of Science ®Google Scholar
• Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour- associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141:672–675. doi:10.1111/j.1365-2141.2008.07077.x18318758
   PubMed Web of Science ®Google Scholar